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Abstract
The accuracy and the reliability of well-recognized clinical, virologic, histologic, and molecular risk factors for hepatocellular carcinoma
(HCC) are still insufﬁcient. Thus, accurate risk prediction of cancer development in individual patients with the aim of selecting high risk
cohorts of patients for HCC chemoprevention programs remains an elusive goal. Future directions in chemoprevention of HCC will be in
the development of molecular risk models and of new chemopreventive agents. Studies examining multiple genes and proteins (genomics and
proteomics) in the same HCCs will be required to evaluate this possibility thoroughly. A strategy aiming at preventing chronic liver disease
of any etiology (HCV and HBV infection, alcohol, obesity, others) may be required to prevent HCC in low and intermediate incidence areas,
and hence, worldwide. In the setting of secondary chemoprevention, literature data pooling suggests a slight preventive effect of interferon
(IFN) on HCC development in patients with HCV-related cirrhosis. The magnitude of this effect is low, and the observed beneﬁt might be due
to spurious associations. The preventive effect is limited to sustained virological responders to IFN. So, there is no sound evidence to support
a recommendation for widespread use of IFN to prevent HCC in HCV-related cirrhosis. In the setting of tertiary chemoprevention, the risk of
recurrence of HCC may be reduced by IFN treatment in selected patient populations. Further large-scale multicenter randomized controlled
trials may prove useful to evaluate the beneﬁt on overall survival.
© 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
Although early diagnosis and effective treatments are
paramount in controlling the death rate of patients with
hepatocellular carcinoma (HCC) [1], the importance of cancer
prevention has gradually emerged because advanced (large
or locally invasive) HCC is difﬁcult to cure [2]. Because
the basic mechanism of all cancer development results from
accumulation of epigenetic and genetic alterations in cells, the
current concept of multistage carcinogenesis has promoted
chemoprevention to the stage of a new medical science [3].
Therefore, HCC (chemo)prevention remains a major issue in
the long-term management of cirrhotic patients, especially in
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compensated cirrhosis of viral aetiology, in which HCC is the
ﬁrst complication to occur and a major cause of liver-related
death [4].
Chemoprevention may be deﬁned as the use of natural or
synthetic agents to reverse, suppress, or prevent premalignant
lesions from progressing to invasive cancer [5]. Chemopre-
vention of HCC may be classiﬁed into three categories:
1. primary, preventing cancer in healthy subjects at high risk
for etiologic factors known to cause chronic liver disease;
2. secondary, preventing cancer in those with premalignant
conditions, for example, HCC prevention in patients with
cirrhosis;
3. tertiary, preventing recurrence in patients cured of an
initial cancer.
A prevention program for HCC should fulﬁl the following
prerequisites:
1. identiﬁcation of the risk factors for HCC;
2. determination of the pathogenetic mechanisms of liver
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carcinogenesis as well as of the genetic markers that
identify the early events in the carcinogenetic process and
possibly availability of animal tumor models;
3. ﬁnally, evaluation of the available data from epidemiologic
and clinical studies on candidate (chemo)preventive agents.
2. Primary prevention
Because vaccination against HCV is yet unavailable and
there is only a low probability of a vaccine against HCV being
developed in the near future, other preventive methods are
required to reduce the burden of HCV-related liver disease.
Counselling is needed for primary prevention of new infection
by rigorous implementation of infection control practice to
prevent nosocomial and iatrogenic HCV transmission and
secondary prevention of HCV transmission from infected
persons to other persons [6]. However, the impact of any
prevention program on HCV spread is relatively low because
the majority of the infected patients are not under medical
care. Although screening of the whole population is not
recommended, it is important to test for HCV all persons with
risk factors for HCV infection. A strategy aiming at preventing
chronic liver disease of any etiology (alcohol, obesity, others)
may be required to prevent HCC in low- and intermediate-
incidence areas, and hence, worldwide. The incidence of
HCC might be further reduced by eliminating aﬂatoxin from
the food supply in areas of the world where agricultural
products are stored under conditions that favour the growth
of Aspergillus ﬂavus and Aspergillus parasiticus. A recent
case-control study conducted in Sudan clearly demonstrated
that reduction of aﬂatoxin contamination of foods may be a
useful public health strategy in HCC prevention [7]. Other
risk factors, like anabolic or sex steroids, smoking habits,
and perhaps plant-derived or chemical agents have not been
considered, because their impact on HCC epidemiology is
doubtful or very small, and available data are sparse and
somewhat conﬂicting.
3. Secondary prevention
The role of interferon (IFN) in preventing HCC in HCV
related cirrhosis is controversial. It has been argued that long-
term suppression of viral replication could reduce hepatocyte
turnover and lessen the risk of dysplasia and cancer. In 1995,
a small randomized controlled trial (RCT) showed a decrease
in the incidence of HCC in patients with HCV cirrhosis
compared with untreated controls [8]. In the wake of this
study, several controlled trials [9–27] were performed. These
studies, often assessed retrospectively, collected cohorts of
a relatively small size and having a marked degree of
heterogeneity, making it difﬁcult to assess the actual level of
beneﬁt obtained by IFN treatment. Moreover, these studies
have been subjected to many criticisms because of several
methodological ﬂaws, their results being largely inconsistent.
This can be explained, at least in part, by differences in
design, stage of disease, duration of follow up, type of
IFN, and schedule of treatment. The main reason for these
discrepancies, however, most likely derives from the many
limitations of retrospective studies, such as susceptibility,
intervention, and selection biases, that may make the results
unreliable. Finally these studies were not primarily designed,
powered and conducted to assess the beneﬁt of IFN on HCC
prevention.
Hitherto, a number of important questions still remain
unsolved by the available studies:
– Is the risk of HCC in viral cirrhosis reduced by IFN
therapy?
– If a risk reduction truly exists, does the beneﬁt apply to all
patients with HCV cirrhosis?
– Is a sustained response to IFN required to reduce the
incidence of HCC?
– Does the preventive effect of IFN on HCC development
start before the onset of severe ﬁbrosis or cirrhosis?
Three meta-analyses on aggregate data [28–30] were
performed to evaluate whether IFN reduces the incidence
of HCC in patients with HCV-related cirrhosis. In the last
published [30], IFN seemingly decreased HCC rate in all but
one of 20 studies included in the meta-analysis, a signiﬁcant
difference being observed in 13 studies.
The rate difference (RD) between IFN-treated patients and
controls of each trial ranged from −33.3% to +3.9%. The
pooled estimate of the treatment effect was signiﬁcantly in
favour of a preventive effectiveness of IFN (RD, −12.2%;
95% CI, −8.4% to −16.1%, P < 0.00001). A remarkable
heterogeneity among the studies (P < 0.0001) was found.
The most prominent heterogeneity was in the difference of
magnitude of the treatment effect on the risk of cancer (“quan-
titative heterogeneity”). Large differences were observed in
the baseline risk of HCC among the different trials: the HCC
rate in the untreated group ranged from 6.8% to 73%.
All meta-analyses [28–30] clearly showed that the hetero-
geneity in HCC incidence in patients who received IFN is the
most relevant feature of the studies. The inconsistency among
these trials is not surprising if one considers all potential
biases in the selection of patients with different demographic
and clinical characteristics, different timing of referral and
diagnostic criteria, true differences in case mix, risk factors
for HCC development, severity of the underlying cirrhosis
and dose and length of IFN treatment.
An attempt to explain the wide variability in the risk of
HCC development was made by stratifying studies according
to variables that described the patients studied (patient-
level covariates) and the study design features (study-level
covariates). A signiﬁcant heterogeneity in IFN beneﬁt among
studies remained even after stratifying by study- and patient-
level covariates. However, heterogeneity in the prevention
effect of IFN on HCC development disappears in the stratum
of sustained responders, implying that viral clearance seems
to inﬂuence the clinical beneﬁt.
A meta-analysis [30] clearly showed that the overall effect
of IFN on HCC development was inﬂuenced by the Japanese
studies, which had the highest incidence of HCC in untreated
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patients. This may be explained by the intensiveness of the
screening programs. Genetic and dietary factors, different
strains of HCV, age-speciﬁc distribution of infection or HBV
occult infection and different molecular characteristics and
biological behaviour of the tumour may also account for the
difference in HCC incidence observed between European and
Japanese patients.
Firm conclusions, drawn on the results of direct com-
parisons between treated and untreated cirrhotic patients,
are seriously hampered by the fact that the majority of the
studies included in the meta-analyses were non randomized
controlled trials (NRCT) and only three small RCTs were
originally designed to perform this comparison. NRCTs are
subject to many problems that reduce their internal and ex-
ternal validity. Their lack of precision and reliability causes
inherent biases towards false positive results [31]. When as-
sessing NRCTs, the most important bias is the likelihood of
inappropriate selection of patients, which can lead to incor-
rect results and spurious associations. Therapeutic guidelines
cannot be derived from NRCTs unless the observed beneﬁt
of treatment is large, the treated group strictly comparable
to external controls, and the clinical course of untreated pa-
tients predictable by a reliable prognostic model. None of the
NRCTs of IFN for HCC prevention in viral cirrhosis fulﬁls
these methodological standards.
So, the available evidence from meta-analyses is sufﬁcient
to conclude that IFN may prevent or delay the development
of HCC in patients with HCV-related cirrhosis. However,
the magnitude of the overall effect is low and the observed
beneﬁt might be due to spurious associations. The preventive
effect is stronger among sustained responders to IFN, which
intrinsically represent a small proportion of all cirrhotic
patients.
After the meta-analyses, 3 observational cohort studies,
two prospective studies conducted in Japan [32] and in
Taiwan [33] and one retrospective study conducted in Italy
[34], have clearly conﬁrmed that the efﬁcacy of IFN in
the chemoprevention of HCC is exclusively linked to the
achievement of a sustained viral eradication, while no beneﬁt
in reducing HCC development was observed in non-responder
patients.
Recently, the effectiveness of long-term maintenance ther-
apy with pegylated-IFN at low dose in non-responder patients
with advanced ﬁbrosis or HCV-related cirrhosis was evaluated
by 3 RCTs: the HALT-C trial [35], the Epic-3 trial [36] and
the COPILOT trial [37]. Patients in these studies were quite
homogeneous in terms of recruitment criteria, stage of liver
disease at entry, follow up and treatments. The outcomes
assessed were death, hepatic decompensation as deﬁned by
Child-Pugh score progression, HCC, and, for non-cirrhotic
patients, an increase in hepatic ﬁbrosis.
Not surprisingly, in all the 3 RCTs the proportion of cir-
rhotic patients who developed clinical outcomes was similar
in the treatment and control group. The 3 studies show that
the natural history of cirrhosis was not signiﬁcantly affected
by low-dose PEG-IFN maintenance treatment as both overall,
event free survival and HCC development did not differ
between treated and untreated patients. So, no beneﬁt of
maintenance therapy in reducing the progression of ﬁbrosis,
hepatic decompensation, mortality, or in preventing the devel-
opment of HCC was observed, despite the improvement of
inﬂammatory markers (alanine aminotransferase and necroin-
ﬂammatory histologic ﬁndings) and the reduction of viral
load. It seems reasonable, therefore, to recommend caution
when treating cirrhotic patients to reduce the risk of cancer
with long-term maintenance IFN regimens.
The negative results of these large multicentre RCTs were
fully expected, based on the following considerations:
First, the hypothesis that a long-term suppression of HCV
replication in the absence of a complete viral eradication
could slow or block the mechanisms of carcinogenesis has
low biological plausibility. In contrast to the data regarding
carcinogenesis by HBV, there is currently no sound evidence
in the literature that the risk of developing HCC is correlated
with the levels of HCV replication.
Second, our previous meta-analysis [38] had already
clearly demonstrated that the histological improvement of
ﬁbrosis was clearly observed only in patients with a sustained
virological response to therapy while in nonresponders we did
not ﬁnd any signiﬁcant regression of ﬁbrosis.
Third, previous evidence from literature data pooling
clearly suggested that the preventive effect of IFN on HCC
development in patients with HCV-related cirrhosis was
observed only among sustained responders to IFN.
Fourth, the low doses of PEG-IFN used in the 3 RCTs
make the probability of demonstrating a signiﬁcant clinical
beneﬁt very unlikely.
Finally, considering the difﬁculties in planning and con-
ducting long-term randomised clinical trials, a prospective
trial aimed at assessing the efﬁcacy of IFN in preventing HCC
should have been conducted in a selected population at high
risk for HCC development.
4. Tertiary chemoprevention
The 3-year survival rate of patients with HCC undergoing
surgical or percutaneous ablation remains low, because of the
high risk of intra-hepatic recurrence even though treatment
has been considered curative by imaging technique. A plateau
in the effectiveness of ablative treatment may well have
been reached, and further improvement in survival from a
single-modality approach seems unlikely.
Cammà et al. [39] who followed a large cohort (more than
200) of patients with small (<5 cm) HCC in compensated
cirrhosis treated by radiofrequency thermal ablation (RFTA),
reported that the 3-year recurrence rate of new lesions was
34%, quite similar to that of a previous study on percutaneous
ethanol injection (PEI) (41%) of the same group [40], and
also similar to that found in the study by Lencioni et al.
[41], in which the 2-year recurrence rate of patients treated by
radiofrequency thermal ablation was 36%. Therefore, all these
data underscore, from a practical point of view, the need for
adjuvant therapy (tertiary prevention) in the effort to prolong
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survival and reduce recurrence rates. In the past, different
anticancer agents have been evaluated for tertiary prevention
of HCC recurrence, including retinoids [42], intra-arterial
I-131 [43], adoptive immunotherapy [44], and ﬁnally IFN
[45–49]. Recently, sorafenib, an oral multi-kinase inhibitor
targeting both tumor cells and the tumor vasculature is
being evaluated in the setting of tertiary chemoprevention.
Two large multinational randomized, double blind, placebo-
controlled trials are currently in progress to evaluate the
efﬁcacy (overall survival and cancer-free survival) and the
tolerability of sorafenib versus placebo as adjuvant treatment
in subjects with HCC following potentially curative treatment
(surgical resection or local ablation) or palliative treatment
(transcatheter arterial chemoembolization – TACE).
5. Interferon
The potential activity of IFN in the setting of secondary
chemoprevention has led to the treatment of patients with
IFN in the adjuvant setting. Since the ﬁrst RCT of IFN
adjuvant therapy appeared in 2000 [45], four other RCTs
have been published [46–49]. Studies have indicated that IFN
decreases the rate of HCC recurrence, and the results of
our meta-analysis, totalling 196 patients, consistently show
a statistically signiﬁcant beneﬁt on HCC recurrence. IFN
was superior to no treatment in all trials, reaching statistical
signiﬁcance in all but one study. The pooled estimate of the
treatment effect was signiﬁcantly in favour of a beneﬁcial
effect of IFN on HCC recurrence (RD, −43%; 95% CI,
−65% to −20%, P < 0.0001). No signiﬁcant heterogeneity
was found among the ﬁve trials. The NNT, i.e. the number
of patients with HCC receiving potentially curative treatments
needed to treat with IFN to prevent one cancer recurrence,
was 2. However, the key clinical question is whether all
patients with HCC receiving potentially curative treatments
should and could be treated with IFN or whether adjuvant
treatment should be administered only to a selected group of
patients who clearly stand to beneﬁt. Unfortunately, there is
no reliable predictive model capable of identifying patients
with HCC receiving potentially curative treatments at high
risk of developing HCC recurrence. Furthermore, all the
RCTs in the tertiary setting have been conducted in the
eastern populations limiting the external validity of these
studies and therefore making the transferability of the results
to different populations questionable. Further large-scale
multicenter RCTs designed and conducted also in western
populations may prove useful to substantiate the beneﬁt on
recurrence and overall survival.
Recently, Mazzaferro and coworkers published a RCT [50]
on a group of 150 early or intermediate HCV-related HCC
patients undergoing resection and stratiﬁed into 80 HCV-
pure (hepatitis B anticore antibody [anti-HBc]-negative) and
70 HCV mixed (anti-HBc-positive) groups, then randomized
to IFN-α (3 million units 3 times weekly for 48 weeks
[n = 76]) versus control (n = 74). While no treatment effect
was apparent in the mixed HCV + HBV population and
on early recurrences, there was a signiﬁcant beneﬁt on
late recurrences in HCV-pure patients adherent to treatment.
Authors concluded that IFN does not affect overall prevention
of HCC recurrence after resection, but it may reduce late
recurrence in HCV-pure patients receiving effective treatment.
6. Acyclic retinoids
Retinoids, acting on nuclear receptors, retinoic acid recep-
tor (RAR) and retinoid X receptor (RXR) have potential for
cancer chemoprevention through their action as regulators of
cell growth and differentiation [51]. Retinoids may inhibit or
reverse the carcinogenic process in various types of cancers,
including the liver, in experimental models of oncogenesis.
A preventive approach to HCC using a synthetic retinoid
analog, acyclic retinoid, has theoretical interest, because post-
translational modiﬁcation of RXR by phosphorylation impairs
its function, leading to uncontrolled hepatocyte growth. In
vitro acyclic retinoid suppresses the phosphorylation of nu-
clear retinoid X receptor α (RXRα), restores its function in the
presence of its endogenous ligand, 9-cis RA, and thereby in-
duces apoptosis of the cancer cells. HCC in cirrhotic patients
contains lower levels of endogenous retinoids, and may be
insensitive to retinoic acid because of a malfunction of RXRα
[50]. In HCC tissues, there is an accumulation of phospho-
inactivated RXRα, which functions as a dominant negative
receptor and interferes with transactivation by remaining
normal RXRα. Acyclic retinoid prevents phosphorylation of
RXRα and restores its function and enhances the sensitivity
of HCC cells to IFNs-α and -β, thereby promoting apoptosis
induced by these interferons. This could lead to eradication
of (pre)malignant clones (“clonal deletion”) from the cirrhotic
liver.
Clinical use of polyprenoic acid, an orally absorbable
acyclic retinoid, has been exploited in the context of tertiary
prevention of HCC recurrence after surgical or PEI tumor
ablation in 89 patients with cirrhosis [52]. Treatment with
polyprenoic acid signiﬁcantly reduced the incidence of re-
current or new cancer lesions. After a median follow-up of
38 months, 12 patients in the polyprenoic acid group (27%)
had recurrent or new HCCs compared with 22 patients in the
placebo group (49%, P = 0.04). These promising results still
await conﬁrmation by other controlled studies.
7. Summary
The accuracy and the reliability of well-recognized clin-
ical, virologic, histologic, and molecular risk factors for
HCC are still insufﬁcient; thus, accurate risk prediction of
developing cancer in individual patients remains an elu-
sive goal. Future directions in chemoprevention of HCC
will be in the development of new molecular risk models
and of new chemopreventive agents. The design of targeted
molecular therapies may need to be tailored to the speciﬁc
molecular phenotype of a speciﬁc HCC. Studies examining
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multiple genes and proteins (genomics and proteomics) in
the same HCCs will be required to evaluate this possibility
thoroughly.
In the setting of secondary chemoprevention, literature
data pooling suggests a slight preventive effect of IFN on
HCC development in patients with HCV-related cirrhosis. The
magnitude of this effect is low, and the observed beneﬁt might
be due to spurious associations. The preventive effect is more
evident among sustained responders to IFN.
In the setting of tertiary chemoprevention, although dif-
ferent agents have been evaluated including retinoids, intra-
arterial I-131, adoptive immunotherapy, and ﬁnally IFN, there
is no sound evidence to support the recommendation for
widespread use of these agents to prevent HCC recurrence
after curative or palliative treatments. The risk of recurrence
of HCC seems reduced by IFN treatment in selected orien-
tal populations only. However, the results are on the whole
inconclusive or conﬂicting and they were not replicated in
most cases. The lack of conclusive evidence of beneﬁt from
the previous therapeutic approaches highlights the urgent and
ongoing need for more effective and safe adjuvant agents
assessed in large-scale multicenter RCTs. Sorafenib is being
evaluated in 2 RCTs designed to assess the effectiveness
of this drug in improving overall survival of patients with
HCC undergoing surgical resection, RFTA or TACE. It is,
therefore, necessary to wait for the results of these RCTs to
implement efﬁcient programs of tertiary chemoprevention in
clinical practice.
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